Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemother...

Descripción completa

Detalles Bibliográficos
Autores: Conteduca, V., Wetterskog, D., Sharabiani, Mansour T. A., Grande, Enrique, Fernández-Pérez, M. P., Jayaram, A., Castellano-Castillo, Daniel, Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vázquez-Estévez, Sergio, González del Alba, Aránzazu, Mellado González, Begoña, Fernández-Calvo, Ovidio, Méndez-Vidal, María J., Climent, Miguel A., Durán, Ignacio, Gallardo, Eduard, Rodríguez, A., Santander, Carmen, Sáez, María Isabel, Puente Vázquez, Javier, Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., de Giorgi, U., González-Billalabeitia, E., Attard, G.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/182664
Acceso en línea:http://hdl.handle.net/10261/182664
Access Level:acceso abierto
Palabra clave:Castration-resistant prostate cancer
Androgen receptor
Plasma DNA
Enzalutamide
Abiraterone
Biomarkers
Descripción
Sumario:[Background] There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.

Similares en LA Referencia